Mindaugas Galvosas, MD
@mgalvosas.bsky.social did:plc:obfvh5sbhlapv2nooimkthu3
Neuroscience Digital Biomarkers @ indivi.io | prev. cough as a digital biomarker @ hyfe.com; founder of wandering prevention tech for dementia | interested in Digital Health | my opinions
Bei Bluesky seit
- Follower
- 4.072
- Folgt
- 2.253
- Posts
- 991
- Tage in Ranglisten
- 0
Zusammenfassung
Mindaugas Galvosas, MD (@mgalvosas.bsky.social) ist seit 7 Februar 2024 auf Bluesky. Das Konto hat 4.072 Follower, folgt 2.253 Konten und hat 991 Posts veröffentlicht.
Ranglisten-Platzierungen
Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.
Dieses Konto war noch in keiner Tagesrangliste.
Zuletzt gelikte Posts
Öffentliche Likes aus dem Bluesky-Netzwerk.
Giving up on deep space tonight with such a bright, but beautiful moon! #astrophotography
Post anzeigenIf you haven’t read it yet👇 Sample Size and Power Calculations Based on Endpoint Responsiveness: Applications to Trials of Disease-Modifying Therapies in Parkinson’s Disease www.medrxiv.org/content/10.6...
Post anzeigenIt was a really successful International Parkinson and Movement Disorder Society congress in Seoul this year for Indivi #MDSCongress #MDS2026
Post anzeigenDo all DM1 therapies need to be oligonucleotides? What about: -> small molecules? -> engineered RNA-binding proteins? -> gene and repeat targeting? -> drug repurposing? Future DM1 therapies discussed at #WMS2026 will extend beyond oligonucleotides alone
Post anzeigenIn his #WMS2026 talk "Advances in Translational Therapeutics for DM1," Prof. Masayuki Nakamori (Yamaguchi University) highlighted how quickly the DM1 pipeline has matured, and also what remains to be solved: the endpoint
Post anzeigen
Blockierte Konten
Blockierungen sind auf Bluesky öffentlich.
